Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19
Pfizer
AUGUST 15, 2022
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1
Let's personalize your content